当前位置：
X-MOL 学术
›
J. Cardiovasc. Pharmacol. Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A Comprehensive Review of PCSK9 Inhibitors
Journal of Cardiovascular Pharmacology and Therapeutics ( IF 2.6 ) Pub Date : 2022-05-20 , DOI: 10.1177/10742484221100107 Caroline Coppinger 1, 2 , Mohammad Reza Movahed 2, 3 , Veronica Azemawah 1, 2 , Lee Peyton 4 , James Gregory 1, 2 , Mehrnoosh Hashemzadeh 1, 3
Journal of Cardiovascular Pharmacology and Therapeutics ( IF 2.6 ) Pub Date : 2022-05-20 , DOI: 10.1177/10742484221100107 Caroline Coppinger 1, 2 , Mohammad Reza Movahed 2, 3 , Veronica Azemawah 1, 2 , Lee Peyton 4 , James Gregory 1, 2 , Mehrnoosh Hashemzadeh 1, 3
Affiliation
Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) ...
中文翻译：
PCSK9抑制剂的综合评价
心血管疾病 (CVD) 是美国和全世界的主要死亡原因。这种情况的一个主要风险因素是血清低密度脂蛋白胆固醇（LDL-C）升高......
更新日期：2022-05-20
中文翻译：
PCSK9抑制剂的综合评价
心血管疾病 (CVD) 是美国和全世界的主要死亡原因。这种情况的一个主要风险因素是血清低密度脂蛋白胆固醇（LDL-C）升高......
京公网安备 11010802027423号